MOV10

Summary

MOV10 (Mov10 RNA helicase, HGNC:7200) is a protein-coding gene on chromosome 1p13.2, encoding Helicase MOV-10 (Q9HCE1). 5’ to 3’ RNA helicase that is involved in a number of cellular roles ranging from mRNA metabolism and translation, modulation of viral infectivity, inhibition of retrotransposition, or regulation of synaptic transmission.

Enables 5’-3’ RNA helicase activity and RNA binding activity. Involved in defense response to virus and mRNA destabilization. Located in P-body and cytosol. Implicated in hypertension.

Source: NCBI Gene 4343 — RefSeq curated summary.

At a glance

• GWAS associations: 44
• Clinical variants (ClinVar): 153 total
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001321324

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7200
Approved symbol	MOV10
Name	Mov10 RNA helicase
Location	1p13.2
Locus type	gene with protein product
Status	Approved
Aliases	gb110, MGC2948, fSAP113
Ensembl gene	ENSG00000155363
Ensembl biotype	protein_coding
OMIM	610742
Entrez	4343

Gene structure

Transcript identifiers

Ensembl transcripts: 41 — 21 protein_coding, 12 retained_intron, 7 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000357443, ENST00000369644, ENST00000369645, ENST00000413052, ENST00000465579, ENST00000468624, ENST00000471160, ENST00000475429, ENST00000481711, ENST00000482545, ENST00000486416, ENST00000488160, ENST00000490413, ENST00000494319, ENST00000495374, ENST00000496577, ENST00000685268, ENST00000686097, ENST00000686428, ENST00000686923, ENST00000687174, ENST00000687333, ENST00000687509, ENST00000688698, ENST00000689955, ENST00000690243, ENST00000885023, ENST00000885024, ENST00000885025, ENST00000885026, ENST00000885027, ENST00000885028, ENST00000923694, ENST00000923695, ENST00000923696, ENST00000923697, ENST00000923698, ENST00000923699, ENST00000923700, ENST00000948326, ENST00000948327

RefSeq mRNA: 7 — MANE Select: NM_001321324 NM_001130079, NM_001286072, NM_001321324, NM_001369507, NM_001389562, NM_001389563, NM_020963

CCDS: CCDS65615, CCDS853

Canonical transcript exons

ENST00000369645 — 21 exons

Exon	Start	End
ENSE00001450533	112674659	112674729
ENSE00003482274	112689415	112689650
ENSE00003498268	112696630	112696846
ENSE00003510951	112698287	112698478
ENSE00003524822	112699894	112699982
ENSE00003527691	112694018	112694172
ENSE00003544567	112699685	112699810
ENSE00003548185	112691665	112691799
ENSE00003553261	112696437	112696534
ENSE00003581241	112700416	112700739
ENSE00003593110	112695416	112695574
ENSE00003599353	112697994	112698111
ENSE00003600039	112688935	112689138
ENSE00003612006	112694453	112694629
ENSE00003619902	112692761	112692929
ENSE00003635003	112689840	112690098
ENSE00003649727	112694749	112694896
ENSE00003649924	112700219	112700340
ENSE00003671190	112698715	112698789
ENSE00003676444	112674848	112675049
ENSE00003688316	112696148	112696251

Expression profiles

Bgee: expression breadth ubiquitous, 232 present calls, max score 97.14.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.0284 / max 101.8844, expressed in 1815 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
4693	4.2534	1530
4696	4.1313	1548
4698	3.0022	1352
4699	2.2686	1156
4700	1.9422	1180
4692	1.8654	1103
4695	1.4218	893
4697	1.0645	616
4694	0.7212	436
4701	0.3576	174

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	97.14	gold quality
left testis	UBERON:0004533	96.84	gold quality
right uterine tube	UBERON:0001302	96.48	gold quality
adenohypophysis	UBERON:0002196	96.39	gold quality
right lobe of liver	UBERON:0001114	96.21	gold quality
granulocyte	CL:0000094	95.76	gold quality
lower esophagus mucosa	UBERON:0035834	95.64	gold quality
upper arm skin	UBERON:0004263	95.61	gold quality
skin of abdomen	UBERON:0001416	95.56	gold quality
mucosa of transverse colon	UBERON:0004991	95.40	gold quality
right adrenal gland cortex	UBERON:0035827	95.27	gold quality
right adrenal gland	UBERON:0001233	95.14	gold quality
metanephros cortex	UBERON:0010533	95.11	gold quality
pituitary gland	UBERON:0000007	95.03	gold quality
testis	UBERON:0000473	94.87	gold quality
right ovary	UBERON:0002118	94.80	gold quality
skin of leg	UBERON:0001511	94.79	gold quality
spleen	UBERON:0002106	94.61	gold quality
right lobe of thyroid gland	UBERON:0001119	94.50	gold quality
left adrenal gland cortex	UBERON:0035825	94.39	gold quality
endocervix	UBERON:0000458	94.35	gold quality
left adrenal gland	UBERON:0001234	94.35	gold quality
left ovary	UBERON:0002119	94.35	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.34	gold quality
left uterine tube	UBERON:0001303	94.31	gold quality
ectocervix	UBERON:0012249	94.11	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.96	gold quality
body of uterus	UBERON:0009853	93.84	gold quality
apex of heart	UBERON:0002098	93.62	gold quality
adrenal cortex	UBERON:0001235	93.55	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.65

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting MOV10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-12130	99.75	65.47	452
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-4524A-5P	99.57	71.73	1193
HSA-MIR-4524B-5P	99.57	71.68	1195
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-361-3P	99.19	66.45	1381
HSA-MIR-3940-5P	99.14	65.26	493
HSA-MIR-4507	99.14	65.27	515
HSA-MIR-1909-3P	99.03	66.56	1662
HSA-MIR-153-3P	98.96	72.51	1644
HSA-MIR-374B-3P	98.63	68.24	1360
HSA-MIR-138-5P	98.43	70.49	1292
HSA-MIR-6842-3P	98.07	66.33	1325
HSA-MIR-503-5P	97.87	66.83	575
HSA-MIR-3652	97.71	65.43	1890
HSA-MIR-4430	97.47	65.61	1813

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 29)

• Mov10 coimmunoprecipitates with human Ago1 and Ago2 and also colocalizes with them in cytoplasmic P-bodies. (PMID:16289642)
• The identification of capped small RNAs and the involvement of MOV10 in hepatitis delta virus replication further suggest a conserved mechanism related to RNA-directed transcription in lower eukaryotes. (PMID:18552826)
• These data suggest that MOV10 is involved in the progression of telomerase-catalyzing reaction via the interaction of telomerase protein and telomere DNA. (PMID:19665004)
• Results suggest that Mov10 could be required during the lentiviral lifecycle and that its perturbation disrupts generation of infectious viral particles. (PMID:20140200)
• MOV10, co-purifies and interacts with components of Polycomb-repressive complex 1 from human cells. Knockdown of MOV10 in human fibroblasts leads to the upregulation of the INK4a. (PMID:20543829)
• identified two critical MOV10 packaging determinants and eight other critical residues for anti-HIV-1 activity (PMID:22105071)
• Depletion of endogenous MOV10 significantly enhances the retrotransposition of endogenous retroelements. (PMID:22727223)
• APOBEC3G inhibits microRNA-mediated repression of translation by interfering with the interaction between Argonaute-2 and MOV10 (PMID:22791714)
• MOV10 contributes to the cellular control of long interspersed element 1 replication. (PMID:23754279)
• Authors conclude that HIV-1 virion incorporation and the antiviral activities of Mov10 and APOBEC3G do not require their localization to P bodies. (PMID:23926332)
• Association of the SNP rs2932538 in MOV10 and SNP rs4373814 in CACNB2 with an increased risk of hypertension in a Chinese Han population. (PMID:24338417)
• Results show that MOV10 predominantly binds to 3’ UTRs upstream of regions predicted to form local secondary structures and provide evidence that MOV10 helicase mutants are impaired in their ability to translocate 5’ to 3’ on their mRNA targets. (PMID:24726324)
• A dual function for MOV10 in regulating translation: it facilitates microRNA-mediated translation of some RNAs, but it also increases expression of other RNAs by preventing AGO2 function. (PMID:25464849)
• The endogenous Mov10 could promote hepatitis B virus replication in vitro. (PMID:25533532)
• The DEAG-box of huamn MOV10 was required for the enhancement of Rev/RRE-dependent nuclear export. (PMID:26379090)
• MOV10 acts as an anti-influenza virus factor through specifically inhibiting the nuclear transportation of nucleoprotein and subsequently inhibiting the function of the viral ribonucleoprotein complex (PMID:26842467)
• these results establish MOV10, an evolutionary conserved protein involved in RNA silencing, as an antiviral gene against RNA viruses that uses an retinoic acid-inducible gene I-like receptor-independent pathway to enhance IFN response (PMID:27016603)
• MOV10 is a highly conserved cellular protein belonging to SF1 helicase family that plays critical roles in EV71 infection (PMID:27666477)
• IRAV is an RNA binding protein and localizes to cytoplasmic processing bodies (P bodies) in uninfected cells, where it interacts with the MOV10 RISC complex RNA helicase, suggesting a role for IRAV in the processing of viral RNA. (PMID:27974568)
• Through interference with the ubiquitin-proteasome system, MOV10 enhances the level of apolipoprotein-B-mRNA-editing enzyme catalytic polypeptide-like 3G in HIV-1-infected cells and virions, and synergistically inhibits the replication and infectivity of HIV-1. (PMID:29258557)
• MOV10 interacts with RNASEH2, and their interplay is crucial for restricting L1 retrotransposition. (PMID:29315404)
• the antiviral activity of MOV10 is partially countered by viral NS1 protein that interferes with the interaction of MOV10 with viral NP and causes MOV10 degradation through the lysosomal pathway. (PMID:30617221)
• MOV10 / circ-DICER1 / miR-103a-3p (miR-382-5p) / ZIC4 pathway plays a vital role in regulating the angiogenesis of glioma. (PMID:30621721)
• MOV10 restricts hepatitis B virus replication by inhibiting viral reverse transcription (PMID:31722967)
• The association of MOV10 polymorphism and expression levels with preeclampsia in the Chinese Han population. (PMID:33269545)
• Association study of hypertension susceptibility genes ITGA9, MOV10, and CACNB2 with preeclampsia in Chinese Han population. (PMID:33491517)
• CRL4-DCAF12 Ubiquitin Ligase Controls MOV10 RNA Helicase during Spermatogenesis and T Cell Activation. (PMID:34065512)
• MOV10 recruits DCP2 to decap human LINE-1 RNA by forming large cytoplasmic granules with phase separation properties. (PMID:37437058)
• S100A16 stabilizes the ITGA3-mediated ECM-receptor interaction pathway to drive the malignant properties of lung adenocarcinoma cells via binding MOV10. (PMID:39450567)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	mov10a	ENSDARG00000015829
danio_rerio	mov10b.2	ENSDARG00000056065
danio_rerio	mov10b.1	ENSDARG00000061177
mus_musculus	Mov10	ENSMUSG00000002227
rattus_norvegicus	Mov10	ENSRNOG00000012946
caenorhabditis_elegans	Y106G6D.5	WBGENE00014965
caenorhabditis_elegans	sosi-1	WBGENE00016565
caenorhabditis_elegans	eri-7	WBGENE00016566

Paralogs (10): UPF1 (ENSG00000005007), AQR (ENSG00000021776), MOV10L1 (ENSG00000073146), SETX (ENSG00000107290), ZNFX1 (ENSG00000124201), HELZ2 (ENSG00000130589), IGHMBP2 (ENSG00000132740), DNA2 (ENSG00000138346), CT55 (ENSG00000169551), HELZ (ENSG00000198265)

Protein

Protein identifiers

Helicase MOV-10 — Q9HCE1 (reviewed: Q9HCE1)

Alternative names: Armitage homolog, Moloney leukemia virus 10 protein

All UniProt accessions (5): Q9HCE1, A0A8I5KXC3, A0A8I5KZ07, A0A8I5QKW4, Q5JR04

UniProt curated annotations — full annotation on UniProt →

Function. 5’ to 3’ RNA helicase that is involved in a number of cellular roles ranging from mRNA metabolism and translation, modulation of viral infectivity, inhibition of retrotransposition, or regulation of synaptic transmission. Plays an important role in innate antiviral immunity by promoting type I interferon production. Mechanistically, specifically uses IKKepsilon/IKBKE as the mediator kinase for IRF3 activation. Blocks HIV-1 virus replication at a post-entry step. Counteracts HIV-1 Vif-mediated degradation of APOBEC3G through its helicase activity by interfering with the ubiquitin-proteasome pathway. Also inhibits hepatitis B virus/HBV replication by interacting with HBV RNA and thereby inhibiting the early step of viral reverse transcription. Contributes to UPF1 mRNA target degradation by translocation along 3’ UTRs. Required for microRNA (miRNA)-mediated gene silencing by the RNA-induced silencing complex (RISC). Required for both miRNA-mediated translational repression and miRNA-mediated cleavage of complementary mRNAs by RISC. In cooperation with FMR1, regulates miRNA-mediated translational repression by AGO2. Restricts retrotransposition of long interspersed element-1 (LINE-1) in cooperation with TUT4 and TUT7 counteracting the RNA chaperonne activity of L1RE1. Facilitates LINE-1 uridylation by TUT4 and TUT7. Required for embryonic viability and for normal central nervous system development and function. Plays two critical roles in early brain development: suppresses retroelements in the nucleus by directly inhibiting cDNA synthesis, while regulates cytoskeletal mRNAs to influence neurite outgrowth in the cytosol. May function as a messenger ribonucleoprotein (mRNP) clearance factor. (Microbial infection) Required for RNA-directed transcription and replication of the human hepatitis delta virus (HDV). Interacts with small capped HDV RNAs derived from genomic hairpin structures that mark the initiation sites of RNA-dependent HDV RNA transcription.

Subunit / interactions. Interacts with DICER1, AGO2, TARBP2, EIF6 and RPL7A (60S ribosome subunit); they form a large RNA-induced silencing complex (RISC). Interacts with APOBEC3G in an RNA-dependent manner. Interacts with TRIM71 (via NHL repeats) in an RNA-dependent manner. Interacts with both protein products of LIRE1, ORF1p and ORF2p. Interacts with TUT4 and, to a lesser extent, TUT7; the interactions are RNA-dependent. Interacts with AGO2, TNRC6B and UPF1; the interactions are direct and RNA-dependent. Interacts with FMR1; this interaction is direct, occurs in an RNA-dependent manner on polysomes and induces association of MOV10 with RNAs. Interacts with SHFL; the interaction increases in presence of RNA. Interacts with DHX34; the interaction is RNA-independent. Interacts with IKBKE. Interacts with RBM46. (Microbial infection) Interacts with the human hepatitis delta virus (HDV) antigen HDAg. (Microbial infection) Interacts with HIV-1 protein GAG.

Subcellular location. Cytoplasm. P-body. Cytoplasmic ribonucleoprotein granule. Stress granule. Nucleus.

Post-translational modifications. Ubiquitinated by the DCX(DCAF12) complex that specifically recognizes the glutamate-leucine (Glu-Leu) degron at the C-terminus, leading to its degradation. (Microbial infection) Cleaved and targeted for degradation by picornavirus proteases.

Induction. By herpes simplex 1/HHV-1 virus infection.

Similarity. Belongs to the DNA2/NAM7 helicase family. SDE3 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9HCE1-1	1	yes
Q9HCE1-2	2
Q9HCE1-3	3

RefSeq proteins (7): NP_001123551, NP_001273001, NP_001308253, NP_001356436, NP_001376491, NP_001376492, NP_066014 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026122	MOV-10/SDE3_DEXXQ/H-box	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR041677	DNA2/NAM7_AAA_11	Domain
IPR041679	DNA2/NAM7-like_C	Domain
IPR047187	SF1_C_Upf1	Domain
IPR049075	MOV-10_N	Domain
IPR049077	MOV-10_Ig-like	Domain
IPR049079	Mov-10_helical	Domain
IPR049080	MOV-10-like_beta-barrel	Domain

Pfam: PF13086, PF13087, PF21632, PF21633, PF21634, PF21635

Catalyzed reactions (Rhea), 1 shown:

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)

UniProt features (26 total): mutagenesis site 7, modified residue 6, splice variant 4, sequence conflict 3, region of interest 2, chain 1, short sequence motif 1, compositionally biased region 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCE1-F1	81.19	0.39

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 524–531

Post-translational modifications (6): 969, 977, 148, 160, 254, 432

Mutagenesis-validated functional residues (7):

Position	Phenotype
129	about 70% more antiviral activity against encephalomyocarditis virus replication; when associated with a-869.
530	abolishes 5’ to 3’ directional unwinding activity. abolishes inhibition of rna chaperonne activity of lire1. no effect o
530	attenuated anti-hbv activity.
645	abolishes 5’ to 3’ directional unwinding activity.
646	almost complete loss of the ability to prevent the degradation of apobec3g mediated by hiv-1 vif. attenuated anti-hbv ac
869	about 70% more antiviral activity against encephalomyocarditis virus replication; when associated with a-129.
1002	loss of interaction with dcaf12 and proteasomal degradation.

Function

Pathways and Gene Ontology

Reactome pathways

61 pathways

ID	Pathway
R-HSA-165159	MTOR signalling
R-HSA-1912408	Pre-NOTCH Transcription and Translation
R-HSA-2559580	Oxidative Stress Induced Senescence
R-HSA-2559585	Oncogene Induced Senescence
R-HSA-4086398	Ca2+ pathway
R-HSA-5628897	TP53 Regulates Metabolic Genes
R-HSA-5687128	MAPK6/MAPK4 signaling
R-HSA-8853884	Transcriptional Regulation by VENTX
R-HSA-8934593	Regulation of RUNX1 Expression and Activity
R-HSA-8936459	RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
R-HSA-8943723	Regulation of PTEN mRNA translation
R-HSA-8948700	Competing endogenous RNAs (ceRNAs) regulate PTEN translation
R-HSA-8986944	Transcriptional Regulation by MECP2
R-HSA-9018519	Estrogen-dependent gene expression
R-HSA-9022692	Regulation of MECP2 expression and activity
R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
R-HSA-9725371	Nuclear events stimulated by ALK signaling in cancer
R-HSA-9759811	Regulation of CDH11 mRNA translation by microRNAs
R-HSA-9764562	Regulation of CDH1 mRNA translation by microRNAs
R-HSA-9768778	Regulation of NPAS4 mRNA translation
R-HSA-9824594	Regulation of MITF-M-dependent genes involved in apoptosis
R-HSA-9839394	TGFBR3 expression
R-HSA-9909620	Regulation of PD-L1(CD274) translation
R-HSA-1257604	PIP3 activates AKT signaling
R-HSA-1266738	Developmental Biology
R-HSA-1500931	Cell-Cell communication
R-HSA-157118	Signaling by NOTCH
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-1912422	Pre-NOTCH Expression and Processing

MSigDB gene sets: 0 (showing top):

GO Biological Process (10): transposable element silencing (GO:0010526), regulatory ncRNA-mediated post-transcriptional gene silencing (GO:0035194), miRNA-mediated post-transcriptional gene silencing (GO:0035195), miRNA-mediated gene silencing by mRNA destabilization (GO:0035279), defense response to virus (GO:0051607), positive regulation of mRNA catabolic process (GO:0061014), 3’-UTR-mediated mRNA destabilization (GO:0061158), transposable element silencing by mRNA destabilization (GO:0141008), regulation of neuron projection arborization (GO:0150011), regulatory ncRNA-mediated gene silencing (GO:0031047)

GO Molecular Function (9): RNA binding (GO:0003723), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), 5’-3’ RNA helicase activity (GO:0032574), nucleotide binding (GO:0000166), RNA helicase activity (GO:0003724), helicase activity (GO:0004386), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (8): P-body (GO:0000932), obsolete extracellular space (GO:0005615), nucleus (GO:0005634), cytosol (GO:0005829), cytoplasmic stress granule (GO:0010494), cytoplasmic ribonucleoprotein granule (GO:0036464), P granule (GO:0043186), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-17 pathways:

Category	Pathways
Cellular Senescence	2
Generic Transcription Pathway	2
Transcriptional regulation by RUNX1	2
Signal Transduction	1
Pre-NOTCH Expression and Processing	1
Beta-catenin independent WNT signaling	1
Transcriptional Regulation by TP53	1
MAPK family signaling cascades	1
PTEN Regulation	1
Regulation of PTEN mRNA translation	1
ESR-mediated signaling	1
Transcriptional Regulation by MECP2	1
NR1H2 and NR1H3-mediated signaling	1
Signaling by ALK fusions and activated point mutants	1
Regulation of CDH11 Expression and Function	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mRNA destabilization	3
cytoplasmic ribonucleoprotein granule	3
negative regulation of gene expression	2
ATP-dependent activity	2
cytoplasm	2
cellular anatomical structure	2
retrotransposition	1
post-transcriptional gene silencing	1
regulatory ncRNA-mediated gene silencing	1
regulatory ncRNA-mediated post-transcriptional gene silencing	1
miRNA-mediated post-transcriptional gene silencing	1
defense response	1
response to virus	1
mRNA catabolic process	1
positive regulation of catabolic process	1
regulation of mRNA catabolic process	1
positive regulation of mRNA metabolic process	1
transposable element silencing	1
regulation of cell morphogenesis	1
regulation of cell projection organization	1
neuron projection arborization	1
nucleic acid binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
RNA helicase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
helicase activity	1
ATP-dependent activity, acting on RNA	1
catalytic activity, acting on RNA	1
nucleic acid conformation isomerase activity	1
catalytic activity, acting on a nucleic acid	1
binding	1
catalytic activity	1
intracellular membrane-bounded organelle	1
ribonucleoprotein granule	1
germ plasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

2008 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MOV10	AGO2	Q9UKV8	991
MOV10	DICER1	Q9UPY3	991
MOV10	TNRC6B	Q9UPQ9	978
MOV10	AGO1	Q9UL18	968
MOV10	FMR1	Q06787	875
MOV10	PUM2	Q8TB72	870
MOV10	EIF6	P56537	777
MOV10	FXR2	P51116	759
MOV10	FXR1	P51114	759
MOV10	TNRC6A	Q8NDV7	747
MOV10	APOBEC3G	Q9HC16	739
MOV10	DHX9	Q08211	712
MOV10	UPF1	Q92900	647
MOV10	PABPC1	P11940	642
MOV10	ELAVL1	Q15717	641

IntAct

331 interactions, top by confidence:

A	B	Type	Score
IFIT1	IFIT3	psi-mi:“MI:0914”(association)	0.920
N	MOV10	psi-mi:“MI:0915”(physical association)	0.910
MOV10	N	psi-mi:“MI:0914”(association)	0.910
MOV10	N	psi-mi:“MI:0403”(colocalization)	0.910
DDX21	N	psi-mi:“MI:0914”(association)	0.870
NS	PIK3R2	psi-mi:“MI:0914”(association)	0.750
N	HNRNPR	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
HLA-A	TAPBP	psi-mi:“MI:0915”(physical association)	0.690
MOV10	CBX8	psi-mi:“MI:0915”(physical association)	0.680
MOV10	CBX7	psi-mi:“MI:0915”(physical association)	0.680
MOV10	CBX7	psi-mi:“MI:0914”(association)	0.680
MOV10	CBX6	psi-mi:“MI:0915”(physical association)	0.670
H1-1	RRP8	psi-mi:“MI:0914”(association)	0.640
NOP53	RRP8	psi-mi:“MI:0914”(association)	0.640
IGF2BP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
MOV10	BMI1	psi-mi:“MI:0915”(physical association)	0.620
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
MOV10	Cbx7	psi-mi:“MI:0407”(direct interaction)	0.590
MOV10	Cbx7	psi-mi:“MI:0915”(physical association)	0.590
MOV10	IGF2BP1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (1482): NOC2L (Affinity Capture-RNA), AGRN (Affinity Capture-RNA), NADK (Affinity Capture-RNA), PGD (Affinity Capture-RNA), DFFA (Affinity Capture-RNA), SRM (Affinity Capture-RNA), EXOSC10 (Affinity Capture-RNA), MTOR (Affinity Capture-RNA), MAD2L2 (Affinity Capture-RNA), CLCN6 (Affinity Capture-RNA), SZRD1 (Affinity Capture-RNA), UBR4 (Affinity Capture-RNA), MINOS1 (Affinity Capture-RNA), DDOST (Affinity Capture-RNA), E2F2 (Affinity Capture-RNA)

ESM2 similar proteins: A0A8C2MDK8, A0A8I6GM68, A6H751, A7YY46, A8MX76, D3YXS5, D3ZBP4, D3ZEY4, E7F9T0, E9QAM5, F1MH07, F1QCV2, F8WLE0, P16452, P23249, P48760, P49222, P52824, Q2NKY8, Q2QWU2, Q3SYT1, Q3ZBE0, Q4R380, Q50L43, Q5BJS0, Q5NCQ5, Q5R607, Q5RKI3, Q5ZI74, Q69ZP3, Q6P5E8, Q6ZSI9, Q7L2E3, Q8BX80, Q8N490, Q8NFD2, Q8NFI3, Q8TDZ2, Q8TE96, Q8VDP3

Diamond homologs: B6SFA4, D3ZG52, E1BMP7, E9QAM5, F1RCY6, O76512, O94247, O94387, P23249, P30771, P32644, P38935, P40694, P51530, Q00416, Q09449, Q09820, Q0V8H6, Q0VGT4, Q1LXK4, Q54I89, Q57568, Q60560, Q86AS0, Q86YA3, Q8GYD9, Q8QHA5, Q8R151, Q92355, Q92900, Q98TR3, Q9BYK8, Q9EPU0, Q9EQN5, Q9FJR0, Q9HCE1, Q9HEH1, Q9P2E3, Q9VYS3, P39369

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
Interferon-type-I	“up-regulates quantity by expression”	MOV10	“transcriptional regulation”
MOV10	“up-regulates activity”	IKBKE	binding
MOV10	“up-regulates activity”	UPF1	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 203 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of DNA methylation proteins	5	25.8×	7e-04
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	6	13.9×	1e-03
SUMOylation of transcription cofactors	6	11.2×	1e-03
SUMOylation of RNA binding proteins	6	11.0×	1e-03
PTEN Regulation	6	10.5×	1e-03
Regulation of PTEN gene transcription	7	9.6×	1e-03
Signaling by ALK fusions and activated point mutants	7	8.1×	1e-03
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	7	7.9×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of viral genome replication	5	16.3×	2e-03
mRNA stabilization	6	12.3×	2e-03
negative regulation of translation	10	11.0×	3e-05
mRNA export from nucleus	6	10.0×	5e-03
rRNA processing	9	7.2×	1e-03
translation	11	6.3×	6e-04
defense response to virus	11	4.3×	8e-03
protein phosphorylation	11	4.2×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

153 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	107
Likely benign	9
Benign	7

Top pathogenic / likely-pathogenic (0)

SpliceAI

3455 predictions. Top by Δscore:

Variant	Effect	Δscore
1:112689135:ACAG:A	donor_loss	1.0000
1:112689137:AGGT:A	donor_loss	1.0000
1:112689410:CCCA:C	acceptor_loss	1.0000
1:112689413:A:AG	acceptor_gain	1.0000
1:112689413:AG:A	acceptor_gain	1.0000
1:112689414:G:GA	acceptor_loss	1.0000
1:112689414:G:GG	acceptor_gain	1.0000
1:112689414:GG:G	acceptor_gain	1.0000
1:112689414:GGGCT:G	acceptor_gain	1.0000
1:112689651:GTGA:G	donor_gain	1.0000
1:112689653:GA:G	donor_gain	1.0000
1:112689655:G:GG	donor_gain	1.0000
1:112689837:CAG:C	acceptor_loss	1.0000
1:112689839:G:GC	acceptor_loss	1.0000
1:112689839:GGT:G	acceptor_gain	1.0000
1:112690079:G:GT	donor_gain	1.0000
1:112690080:A:T	donor_gain	1.0000
1:112690084:A:T	donor_gain	1.0000
1:112690099:G:GC	donor_loss	1.0000
1:112690099:G:GG	donor_gain	1.0000
1:112691654:C:CA	acceptor_gain	1.0000
1:112691663:A:AG	acceptor_gain	1.0000
1:112691663:AGC:A	acceptor_gain	1.0000
1:112691664:G:GG	acceptor_gain	1.0000
1:112691664:GC:G	acceptor_gain	1.0000
1:112691664:GCG:G	acceptor_gain	1.0000
1:112691664:GCGCT:G	acceptor_gain	1.0000
1:112691800:G:GG	donor_gain	1.0000
1:112691801:TAA:T	donor_loss	1.0000
1:112692756:TCCA:T	acceptor_loss	1.0000

AlphaMissense

6492 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:112696846:G:T	R733M	1.000
1:112694846:G:A	G524R	0.999
1:112694846:G:C	G524R	0.999
1:112694846:G:T	G524W	0.999
1:112694847:G:A	G524E	0.999
1:112694856:G:A	G527D	0.999
1:112694862:G:A	G529D	0.999
1:112694864:A:C	K530Q	0.999
1:112694865:A:T	K530M	0.999
1:112696490:A:C	E646A	0.999
1:112696490:A:T	E646V	0.999
1:112696687:A:G	D680G	0.999
1:112696687:A:T	D680V	0.999
1:112696697:G:C	Q683H	0.999
1:112696697:G:T	Q683H	0.999
1:112696841:C:A	N731K	0.999
1:112696841:C:G	N731K	0.999
1:112696846:G:C	R733T	0.999
1:112699793:T:C	F898L	0.999
1:112699794:T:C	F898S	0.999
1:112699795:C:A	F898L	0.999
1:112699795:C:G	F898L	0.999
1:112699902:T:A	N906K	0.999
1:112699902:T:G	N906K	0.999
1:112699906:G:C	A908P	0.999
1:112699907:C:A	A908D	0.999
1:112699975:T:A	W931R	0.999
1:112699975:T:C	W931R	0.999
1:112694855:G:C	G527R	0.998
1:112694865:A:C	K530T	0.998

dbSNP variants (sampled 300 via entrez): RS1000004804 (1:112687856 G>T), RS1000016671 (1:112692915 C>T), RS1000114216 (1:112701137 C>G,T), RS1000126367 (1:112684181 C>G), RS1000299807 (1:112672644 G>A,T), RS1000374387 (1:112678832 G>A), RS1000397557 (1:112697498 C>G,T), RS1000600476 (1:112689768 T>C), RS1000624231 (1:112673935 T>C), RS1000672184 (1:112691195 G>A,C), RS1000718736 (1:112674197 C>G,T), RS1000728476 (1:112695961 G>A), RS1001400727 (1:112699154 C>T), RS1001748870 (1:112673618 C>T), RS1001827950 (1:112691921 C>G,T)

Disease associations

OMIM: gene MIM:610742 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

44 associations (top):

Study	Trait	p-value
GCST001227_19	Systolic blood pressure	1.000000e-09
GCST001228_13	Diastolic blood pressure	1.000000e-09
GCST001236_18	Blood pressure	8.000000e-06
GCST001238_5	Hypertension	3.000000e-07
GCST002627_6	Hypertension	3.000000e-09
GCST002630_7	Systolic blood pressure	3.000000e-09
GCST002631_11	Diastolic blood pressure	8.000000e-08
GCST004067_194	Hip circumference adjusted for BMI	9.000000e-07
GCST004067_82	Hip circumference adjusted for BMI	6.000000e-09
GCST004776_10	Systolic blood pressure	2.000000e-07
GCST004777_31	Diastolic blood pressure	1.000000e-10
GCST004777_46	Diastolic blood pressure	2.000000e-08
GCST004777_60	Diastolic blood pressure	6.000000e-19
GCST006166_108	Diastolic blood pressure x alcohol consumption interaction (2df test)	5.000000e-20
GCST006167_20	Mean arterial pressure x alcohol consumption interaction (2df test)	1.000000e-09
GCST006258_50	Diastolic blood pressure	9.000000e-10
GCST006259_26	Systolic blood pressure	1.000000e-12
GCST006434_57	Systolic blood pressure x alcohol consumption interaction (2df test)	2.000000e-14
GCST007094_48	Diastolic blood pressure	7.000000e-12
GCST007099_168	Systolic blood pressure	3.000000e-07
GCST007294_13	Body fat distribution (trunk fat ratio)	9.000000e-19
GCST007294_32	Body fat distribution (trunk fat ratio)	1.000000e-08
GCST007295_163	Body fat distribution (leg fat ratio)	8.000000e-07
GCST007295_7	Body fat distribution (leg fat ratio)	7.000000e-16
GCST007703_106	Systolic blood pressure	1.000000e-11
GCST007704_13	Diastolic blood pressure	4.000000e-10
GCST007706_47	Mean arterial pressure	3.000000e-12
GCST007707_93	Hypertension	3.000000e-13
GCST007928_55	Medication use (diuretics)	1.000000e-12
GCST008839_75	Height	2.000000e-15

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0006336	diastolic blood pressure
EFO:0006340	mean arterial pressure
EFO:0008039	BMI-adjusted hip circumference
EFO:0004329	alcohol drinking
EFO:0004341	body fat distribution
EFO:0009928	Diuretic use measurement
EFO:0004771	visual cortical surface area measurement
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness
EFO:0009819	comparative body size at age 10, self-reported
EFO:0007985	platelet crit
EFO:0004309	platelet count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2932538	MOV10		0.00	0
rs12069113	CAPZA1, MOV10		0.00	0

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, decreases methylation	7
trichostatin A	affects cotreatment, decreases expression	3
bisphenol A	increases abundance, decreases expression, increases expression, decreases reaction	2
methacrylaldehyde	increases abundance, affects cotreatment, increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	2
Acrolein	affects cotreatment, increases expression, increases abundance	2
Cisplatin	increases expression, affects cotreatment	2
Ozone	affects cotreatment, increases expression, increases abundance	2
Cyclosporine	decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
ginger extract	decreases reaction, increases abundance, increases expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
decabromobiphenyl ether	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
M-VAC protocol	decreases response to substance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
pentanal	decreases expression	1
CGP 52608	affects binding, increases reaction	1
JP8 aviation fuel	decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
jinfukang	affects cotreatment, increases expression	1
LDN 193189	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	decreases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists